A therapy that transformed adult diabetes care is now extending its impact to younger patients, helping prevent complications before they begin
GLP-1s have been shown to reduce inflammatory markers, which can help calm the inflammatory environment that contributes to pain and disease activity
The SELECT trial with injected semaglutide demonstrated a 20% reduction in the frequency of 3-point MACE outcome in people with preexisting CVD and overweight/obesity without T2D [6], and injected semaglutide has been shown to reduce 3-point MACE outcomes by 26% in patients with pre-existing CVD and T2D [7]
Those with existing cardiovascular conditions should be especially cautious and consult a provider before beginning treatment
This proactive method maintains youthful features before significant aging occurs, often needing less product and producing subtler results
Alcohol, a known irritant to the gastrointestinal system, can exacerbate these symptoms